At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Philadelphia based CFO’ operating in the Therapeutics space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Brian Piper
Chief Financial Officer of Prelude Therapeutics
Brian Piper joined Medgenics as VP, Finance and Investor Relations in April 2014. Prior to joining Medgenics, Mr. Piper served as Senior Director, Strategic Investment Group (SIG), for Shire Pharmaceuticals, LLC from 2010 to 2013, as well as several different finance and business development roles with Shire over the past 13 years. Mr. Piper began his affiliation with Shire in 2002 as Director of Finance for Shire’s North American Development group in Rockville, MD. In 2004 he established Shire’s first US Investor Relations group, based out of Philadelphia. After three years running US Investor Relations, Mr. Piper transitioned to an alliance management role and spent two years overseas in Dublin, Ireland helping establish geographic expansion strategies. Prior to joining Shire, Mr. Piper held strategic planning roles for Celera Genomics, was Controller for a start-up Contract Research Organization, and worked as a program planner and financial analyst for Otsuka Pharmaceuticals, Inc. Mr. Piper received a B.B.A. from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.
Follow Brian Piper:
About Aevi Genomic Medicine, Prelude Therapeutics, Scorpion Therapeutics: Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival and resistance.
Robert Bermon
Chief Financial Officer of Invo HealthCare Holdings
Robert Bermon, CPA brings more than 20 years of senior financial management experience to the Invo Family of Companies and currently serves as the organizations chief Financial Officer. As CFO, Bob oversees the shared services support team which includes accounting, finance and human resources. Prior to Bob joining the team in 2016, he was the Executive Vice President and Chief Financial Officer at Solomon Edwards. Through streamlined business operations, financial controls and processes that drove growth, efficiency and bottom-line profit, Bob was instrumental in building the infrastructure that promoted the company’s growth. Bob’s career started with accounting firm Grant Thornton. Bob holds a Bachelor of Arts in Accounting from Temple University and is a Certified Pubic Account (CPA).
Follow Robert Bermon:
About Invo HealthCare Holdings: Founded in 1993 by Patrick McClain, an Occupational Therapist, and Mary McClain, an Educator.
Reid McCarthy
Consulting Chief Financial Officer of Annovis Bio
Follow Reid McCarthy:
About Annovis Bio: Annovis Bio develops novel treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.
Frank Ruffo
Co-Founder, Chief Financial Officer of Aclaris Therapeutics
Frank Ruffo co-founded Aclaris and has served as Chief Financial Officer since its inception in 2012. He is a senior financial executive with more than 20 years of biotech and specialty pharmaceutical management expertise in early stage through fully commercial operations. From 2014 to 2015, Frank served part time as a financial consultant at Ralexar Therapeutics, Inc. (formerly known as Alexar Therapeutics Inc.), a specialty dermatology company. Frank also served part time as the Chief Financial Officer of VenatoRx Pharmaceuticals Inc., a pharmaceutical company, from 2011 to 2014 and the Chief Financial Officer of BioLeap, Inc. from 2010 to 2013. Prior to joining Aclaris, Frank co-founded and served as Chief Financial Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan in 2011. Prior to joining Vicept Therapeutics, from 1996 to 2008 he served as the Vice President, Finance and Controller of CollaGenex Pharmaceuticals, Inc. Frank is a certified public accountant in Pennsylvania (inactive since 2008). He received his Bachelor of Science in business administration with a major in accounting from La Salle University.
Follow Frank Ruffo:
About Aclaris Therapeutics, Vicept Therapeutics: Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Martin P. Galvan
CFO of Lannett Company
Mr. Martin P. Galvan, CPA, is Chief Financial Officer, Vice President – Finance, Treasurer of Lannett Company Inc. Most recently, he was Chief Financial Officer of CardioNet, Inc., a medical technology and service company. From 2001 to 2007, Mr. Galvan was employed by Viasys Healthcare Inc., a healthcare technology company that was acquired by Cardinal Health, Inc. in June 2007. Prior to the acquisition, he served as Executive Vice President, Chief Financial Officer and Director Investor Relations. From 1999 to 2001, Mr. Galvan served as Chief Financial Officer of Rodel, Inc., a precision surface technologies company in the semiconductor industry. From 1979 to 1998, Mr. Galvan held several positions with Rhone-Poulenc Rorer Inc., a pharmaceutical company, including Vice President, Finance — The Americas; President & General Manager, RPR Mexico & Central America; Vice President, Finance, Europe/Asia Pacific; and Chief Financial Officer, United Kingdom & Ireland. Mr. Galvan began his career with the international accounting firm Ernst & Young LLP. He earned a Bachelor of Arts degree in economics from Rutgers University and is a member of the American Institute of Certified Public Accountants.
Follow Martin P. Galvan:
About Lannett Company: Lannett develops, manufactures, and distributes generic prescription pharmaceutical products in tablet.
Christopher P. Schnittker
SVP and Chief Financial Officer of Echo Therapeutics
Mr. Schnittker brings a broad base of financial experience to Echo Therapeutics. Most recently, he served as Vice President – Administration, Corporate Secretary and Chief Accounting Officer of Soligenix, Inc., a publicly-traded biotechnology company. Prior to that, Mr. Schnittker served as the Senior Vice President and CFO for VioQuest Pharmaceuticals Inc., Micromet Inc., CytogenCorporation, and Genaera Corporation, all publicly-traded biotechnology companies. Mr. Schnittker has also held prior financial management positions at GSI Commerce, Rhône-Poulenc Rorer (now part of Sanofi-Aventis), and PricewaterhouseCoopers. He received his B.A. degree in economics and business from Lafayette College and is a certified public accountant licensed in the State of New Jersey.
Follow Christopher P. Schnittker:
About Echo Therapeutics: Echo Therapeutics develops the Symphony tCGM System, a novel, non-invasive (needle-free) glucose monitoring system for diabetes patients.